Dimitrios Matthaios, Associate Professor of Clinical Oncology at Democritus University of Thrace, shared on LinkedIn:
“Our Research at EMUC 2026 | Brussels, Belgium
I am pleased to share our latest research presented at the European Multidisciplinary Congress on Urological Cancers (EMUC 2026) in Brussels.
Our research team of the Oncology Department – Democritus University of Thrace, Greece, presented a new study entitled:
‘NR3C1 Gene Methylation as a Prognostic Biomarker in Castration-Resistant Prostate Cancer’
Poster P107 | European Urology Supplement, 2026
In this study, we investigated the prognostic significance of NR3C1 promoter methylation in patients with castration-resistant prostate cancer (CRPC), exploring the potential role of epigenetic alterations in disease progression and clinical outcomes.
Key findings:
- NR3C1 promoter methylation was detected in 56.7% of patients (17/30).
- Methylation was significantly associated with higher Gleason scores (p < 0.05).
- Patients with NR3C1 methylation demonstrated significantly worse overall survival (p = 0.019).
These preliminary findings highlight the potential of NR3C1 methylation as a prognostic biomarker in advanced prostate cancer and support further validation in larger patient cohorts.
I would like to sincerely thank all my co-authors and collaborators for their valuable scientific contributions and commitment to our shared research efforts.
Advancing precision oncology through molecular research, collaboration, and innovation.”
You can also read: CIPHER Phase 2 Trial: Carboplatin in HRR-Altered Metastatic Castration-Resistant Prostate Cancer
